A10 Networks ATEN 深 沪
已收盘 08-01 16:00:00 美东时间
17.75
-0.670
-3.64%
华盛通- 最 高18.26
- 今 开18.24
- 成交量 69.32万股
- 最 低 17.67
- 昨 收 18.42
- 总市值 12.79亿
- 52周最高 21.835
- 市盈率 静 26.66
- 换手率 0.96%
- 52周最低 12.21
- 委 比 -92.21%
- 总股本 7208.07万
- 历史最高 21.835
- 量 比 1.02
- 振 幅 3.20%
- 历史最低 2.57
- 每 手 1
- 风险率 1.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Acurx Pharmaceuticals Announces 1-For-20 Reverse Stock Split, Trading Post-Split On August 5, 2025
Acurx's common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025STATEN ISLAND, N.Y., July 31, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a
07-31 21:26
Latent View Analytics Announces Resignation of Chief Client Officer
Latent View Analytics Limited ( ($IN:LATENTVIEW) ) just unveiled an update. Lat...
07-11 15:16
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
Raymond James Remains a Hold on A10 Networks (ATEN)
In a report released today, Simon Leopold from Raymond James reiterated a Hold ...
06-28 01:05
Deutsche Bank Initiates Coverage On A10 Networks with Buy Rating, Announces Price Target of $22
Deutsche Bank analyst Matt Niknam initiates coverage on A10 Networks (NYSE:ATEN) with a Buy rating and announces Price Target of $22.
06-27 23:35
Latent View Analytics Schedules Investor Meeting
Latent View Analytics Limited ( ($IN:LATENTVIEW) ) just unveiled an update. Lat...
06-25 03:35
Sidoti Events, LLC's Virtual June Small-Cap Conference
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Sidoti Events, LLC, an affilia...
06-10 19:30
Acurx Pharma Says Lead Antibiotic Candidate, Ibezapolstat, Is Ready To Advance To International Pivotal Phase 3 Clinical Trials For Treatment Of Patients With C. Difficile Infection
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC
06-09 19:31
A10 Networks (ATEN) Receives a Buy from Sidoti
In a report released today, Anja Soderstrom from Sidoti maintained a Buy rating...
06-05 20:55
